Am J Transplant, Volume 21, Suppl 3 Archives - Page 95 of 139 - ATC Abstracts

2021 American Transplant Congress
Algorithms to Identify Alcoholic Hepatitis Hospitalizations in Patients with Cirrhosis
S. Panchal¹, D. Kaplan², D. Goldberg³, N. Mahmud²
¹Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Gastroenterology, University of Miami Miller School of Medicine, Miami, FL
*Purpose: With the rising proportion of patients receiving liver transplantation for alcoholic hepatitis, it is important to identify methods of ascertaining hospitalizations with alcoholic hepatitis…
2021 American Transplant Congress
Implementation of an Alcohol Screening Program Identifies Active Pre-transplant Drinking and Allows Engagement in Chemical Dependency Treatment
N. Lim¹, T. Leventhal¹, M. Thomson¹, M. Hassan¹, J. Thompson¹, S. Chinnakotla², V. Kirchner², T. Pruett², R. Kandaswamy², V. Humphreville², A. Adams², J. Lake¹
¹Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN, ²Division of Transplantation, University of Minnesota, Minneapolis, MN
*Purpose: Alcohol (ETOH) is an important cause of cirrhosis in the US today. Screening patients for ETOH use prior to LT is important to identify…
2021 American Transplant Congress
Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything
G. T. Schnickel¹, J. Parekh¹, Y. Kono², J. Berumen¹, V. Ajmeera², K. Mekeel¹
¹Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California San Diego, San Diego, CA, ²Division of Gastroenterology, Department of Medicine, University of California San Diego, San Diego, CA
*Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…
2021 American Transplant Congress
Utilization of Pre-Procurement Donor Liver Biopsy in Donation-after-circulatory-Death Liver Transplantation
A. C. Bolognese¹, N. Neidlinger¹, C. Sparks², A. Schneider², A. M. D'Alessandro¹, D. P. Foley¹
¹Department of Surgery, Division of Transplantation, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW Organ and Tissue Donation, Madison, WI
*Purpose: Careful selection of suitable DCD donor livers is critical to obtain optimal transplant outcomes. In order to identify potentially suitable livers prior to DCD…
2021 American Transplant Congress
The Survival Benefits of Using Marginal Allografts in Liver Transplantation
T. H. Malik¹, E. L. Godfrey¹, A. Rana²
¹Baylor College of Medicine, Houston, TX, ²Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
*Purpose: Our study assessed whether using marginal allografts at initial time of listing provided similar or greater survival benefit versus waiting on the transplant waitlist…
2021 American Transplant Congress
Portal Vein Challenges in Pediatric Liver Transplantation: The Utility of Interposition Grafts as an Acceptable Management Strategy
R. Hogen, K. Etesami, J. Cervantes, Y. Kwon, S. Zielsdorf, J. Emamaullee, Y. Genyk
Division of Hepatobiliary and Abdominal Organ Transplantation, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA
*Purpose: To examine our single center experience in the operative management of pediatric liver transplantation (LT) patients with challenging portal vein (PV) anomalies.*Methods: We retrospectively…
2021 American Transplant Congress
Application of Linear Discriminant Analysis (lda) to Differentiate Acute Rejection (ar) and Acute Dysfunction Non-Rejection (adnr) in Liver Transplant Recipients
M. Miller¹, R. Sinha¹, J. Weems¹, J. Holman², M. Altrich¹, S. Kleiboeker¹, J. Levitsky³
¹R&D, Viracor-Eurofins, Lee's Summit, MO, ²Transplant Genomics, Mansfield, MA, ³R&D, Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: Blood-based biomarkers distinguishing acute-rejection (AR) from other causes of graft dysfunction (acute dysfunction non-rejection (ADNR)) would have significant clinical applicability in liver transplant (LT)…
2021 American Transplant Congress
Mortality from Fulminant Myocarditis in Multi-organ Transplant Recipient with Covid-19
K. Mahendraraj, I. Kim, T. Todo, T. Brennan, N. Nissen, K. Kosari, G. Voidonikolas, D. Ramzy
Transplant Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Novel coronavirus infection has been rarely described in multi-organ transplantation. This case highlights the poor prognosis associated with cardiac involvement by SARS-Cov-2 in transplantation,…
2021 American Transplant Congress
Variation in Next of Kin Authorization for Research in Deceased Donor Organ Transplantation: Experience at One Organ Procurement Organization
K. L. Lentine¹, C. Jones¹, W. Cheungpasitporn², R. Rothweiler³, H. Xiao¹, M. Ortigosa-Goggins⁴, G. Marklin³, R. B. Mannon⁵
¹Saint Louis University, St. Louis, MO, ²Mayo Clinic, Rochester, MN, ³Mid-America Transplant, St. Louis, MO, ⁴University of Miami, Miami, FL, ⁵University of Nebraska, Omaha, NE
*Purpose: Research related to deceased donor interventions seeks to address diverse questions to improve the use and outcomes of organ gifts for transplantation. Consent for…
2021 American Transplant Congress
Patient Perspective of the Implementation of Virtual Medicine in a Post-kidney Transplant Clinic
S. Mann¹, M. Kadatz¹, J. Lan¹, O. Johnston¹, C. Luo²
¹Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada, ²Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada
*Purpose: COVID-19 dramatically altered the model of health care delivery for transplant recipients, necessitating the routine use of virtual medicine. This resulted in consequences for…